PMA device
Cologuard
Exact Sciences Corporation · System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection (PHP, Class III) · First FDA decision Aug 11, 2014, newest Jul 20, 2024Colorectal cancer and polyps
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
8
PMA pathway
Device trials
2
Naming "Cologuard"
MAUDE reports
33
Brand "Cologuard", since 2015
PubMed studies
90
Mentioning "Cologuard"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Cologuard
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 8 decisions filed under this name.
- COLOGUARDPMA supplement
P130017-S057 · Decided Jul 20, 2024 · 176 days after receipt · Normal 180 Day Track No User Fee
Device type: System, colorectal neoplasia, DNA methylation and hemoglobin detection (PHP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Older decisions: P130017-S001, P130017
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39276CGS Administrators, LLCUpdated Feb 13, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39262Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39256Palmetto GBAUpdated Mar 4, 2025
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39356WPS Insurance CorporationUpdated Feb 20, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Cologuard", any status and sponsor, newest update first.
- Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and MortalityActive, not recruiting
Exact Sciences CorporationNot on our public-company list
NCT04124406 · 150,000 participants (planned) · Start Oct 18, 2019 · Primary completion Dec 31, 2023
Device: Cologuard · For: Colon Cancer
Sites: Rochester, Minnesota
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Cologuard", and for the whole product code for context.
This brand
33 reports: 20 malfunction, 10 injury, 1 death
Whole product code PHP
33 reports: 20 malfunction, 10 injury, 1 death
Newest reports for this brand
- CologuardOther
MW6004377 · Received Oct 21, 2026 · Event dated May 12, 2026
Device type: System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection (PHP)
Device problem as coded: False Negative Result
Patient problem as coded: Cancer
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2219-2017 · Started Apr 28, 2017 · Posted by FDA Jun 1, 2017
Reason given: Exact Sciences is correcting all Sample Mixer v2 Upgrade units because of incidents of Sample Mixer door damage, which has occurred when the Sample Holder opens during a run and the Sample Holder lid makes contact with the Sample Mixer door.
Cause as FDA categorized it: Device Design · Device type: System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection (PHP)
Published research
The most relevant PubMed records for "Cologuard"[tiab]. The summary above synthesizes these.
- Multitarget Stool DNA Testing (Cologuard) for Colorectal Cancer Screening.
Clebak KT, Nickolich S, Mendez-Miller M · Am Fam Physician · 2022
- Colorectal cancer screening.
Med Lett Drugs Ther · 2019Review
- Cologuard Plus - an at-home stool DNA test for colorectal cancer screening.
Med Lett Drugs Ther · 2025
- The Boseman Effect: A Missed Opportunity?
Kahlam A, Chowdhury S, Kahlam J, et al. · Cureus · 2022
- From Detection to Delay: Real-World Gaps in Post-Cologuard® Colonoscopy Adherence.
Kazi MAI, Qureshi I, Sharma A, et al. · J Gastrointest Cancer · 2025
- Positive Fecal Immunochemical Test or Cologuard in the Era of the Novel Coronavirus Disease-2019 Pandemic.
Young PE, Tadros M, Mago S · Gastroenterology · 2020Letter
- Non-Invasive Colorectal Cancer Screening: An Overview.
Tepus M, Yau TO · Gastrointest Tumors · 2020Review
- Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
Ladabaum U, Mannalithara A, Weng Y, et al. · Gastroenterology · 2024Comparative Study, Research Support, N.I.H., Extramural
- Colorectal Cancer Screening Preferences among Black and Latino Primary Care Patients.
Chablani SV, Cohen N, White D, et al. · J Immigr Minor Health · 2017
- Cologuard test: A Possible Alternate To Colonoscopy?
Karim MA · J Ayub Med Coll Abbottabad · 2017Letter
- Comprehensive Cost Implications of Commercially Available Noninvasive Colorectal Cancer Screening Modalities.
Allen CJ, Bloom N, Rothka M, et al. · J Am Coll Surg · 2023Research Support, Non-U.S. Gov't
- Improving colorectal cancer screening through Cologuard education: a quality improvement initiative in an urban primary care clinic.
Koseki Senda M, Chow D, Dev B, et al. · BMJ Open Qual · 2025
Other devices of this type
Also filed under product code PHP.
- ShieldGuardant Health, Inc. · PMA 2026
- Epi proColonNew Day Diagnostics, LLC · PMA 2016
- SimpleScreen CRCFreenome, LLC · PMA 2026
- ColoHealthNew Day Diagnostics, LLC · PMA 2025
- Multi-Target Stool DNA (mtsDNA) Test, Cologuard PlusExact Sciences Corporation · PMA 2024
- Cologuard Stool DNA-Based Colorectal Cancer Screening TestExact Sciences Corporation · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.